Author

Edward V. Loftus

MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Edward V. Loftus  et al.

TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA
TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA

Edward V. Loftus  et al.

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Edward V. Loftus  et al.

RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

Edward V. Loftus  et al.

RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Edward V. Loftus  et al.

OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE
OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE

Edward V. Loftus  et al.

LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS
LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN’S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS

Edward V. Loftus  et al.

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS
FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Edward V. Loftus  et al.

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS
SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

Edward V. Loftus  et al.

RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY
RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Edward V. Loftus  et al.

Item 1 - 12 / 12
1